Q-omics provides the consensus-scored RN7SKP69 profile across patient tissues and cancer cell-line models. RN7SKP69 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RN7SKP69 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RN7SKP69 RNA expression shows 9,429 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LUAD, LUSC, and SARC as cancer lineages where RN7SKP69 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP69 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP69 survival associations across molecular data types. RN7SKP69 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP69 RNA expression–survival associations across cancer types. High RN7SKP69 expression shows unfavorable associations in THYM, MESO and PCPG, but favorable associations in LUAD, THCA and STAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for RN7SKP69 RNA expression.
This table summarizes RN7SKP69 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP69. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP69 shows lower tumor expression in LUSC, THCA and BRCA. The LUSC box plot shows higher RN7SKP69 RNA expression in normal versus tumor tissue (log2 FC = −0.305, t-test p < 0.001).
This table shows molecular features associated with RN7SKP69 in patient tissues and cancer cell lines. In patient samples, RN7SKP69 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
